BIIB vs. BMY
BIIB (Biogen Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, BIIB returned -3.85%/yr vs 0.60%/yr for BMY. At a 0.29 correlation, their price movements are largely independent.
Performance
BIIB vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIIB achieves a 11.35% return, which is significantly higher than BMY's 3.70% return. Over the past 10 years, BIIB has underperformed BMY with an annualized return of -3.85%, while BMY has yielded a comparatively higher 0.60% annualized return.
BIIB
- 1D
- 3.78%
- 1M
- 4.67%
- YTD
- 11.35%
- 6M
- 8.41%
- 1Y
- 48.63%
- 3Y*
- -13.25%
- 5Y*
- -7.29%
- 10Y*
- -3.85%
BMY
- 1D
- 0.48%
- 1M
- -4.64%
- YTD
- 3.70%
- 6M
- 9.77%
- 1Y
- 19.47%
- 3Y*
- -1.44%
- 5Y*
- 0.60%
- 10Y*
- 0.60%
BIIB vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 11.35% | 15.09% | -40.91% | -6.55% | 15.42% | -2.02% | -17.48% | -1.39% | -5.54% | 12.34% |
BMY Bristol-Myers Squibb Company | 3.70% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Correlation
The correlation between BIIB and BMY is 0.44, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.44 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.39 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.38 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.38 |
Correlation (All Time) Calculated using the full available price history since Sep 18, 1991 | 0.29 |
The correlation between BIIB and BMY shifts across timeframes, from 0.29 (all time) to 0.44 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
BIIB:
$12.48
BMY:
$3.57
BIIB:
15.70
BMY:
15.35
BIIB:
1.09
BMY:
0.88
BIIB:
2.19
BMY:
2.30
BIIB:
$9.86B
BMY:
$48.48B
BIIB:
$5.06B
BMY:
$33.33B
BIIB:
$2.24B
BMY:
$13.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIIB vs. BMY — Risk / Return Rank
BIIB
BMY
BIIB vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIIB | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.47 | 0.74 | +0.74 |
Sortino ratioReturn per unit of downside risk | 2.24 | 1.25 | +0.99 |
Omega ratioGain probability vs. loss probability | 1.26 | 1.15 | +0.11 |
Calmar ratioReturn relative to maximum drawdown | 3.41 | 1.43 | +1.98 |
Martin ratioReturn relative to average drawdown | 8.35 | 3.16 | +5.19 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BIIB | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.47 | 0.74 | +0.74 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.19 | 0.03 | -0.22 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.09 | 0.02 | -0.12 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.23 | 0.34 | -0.12 |
Drawdowns
BIIB vs. BMY - Drawdown Comparison
The maximum BIIB drawdown since its inception was -89.98%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for BIIB and BMY.
Loading charts...
Drawdown Indicators
| BIIB | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.98% | -72.03% | -17.95% |
Max Drawdown (1Y)Largest decline over 1 year | -14.34% | -13.68% | -0.66% |
Max Drawdown (3Y)Largest decline over 3 years | -63.82% | -36.85% | -26.97% |
Max Drawdown (5Y)Largest decline over 5 years | -72.66% | -47.67% | -24.99% |
Max Drawdown (10Y)Largest decline over 10 years | -72.66% | -47.67% | -24.99% |
Current DrawdownCurrent decline from peak | -58.83% | -21.26% | -37.57% |
Average DrawdownAverage peak-to-trough decline | -36.60% | -22.38% | -14.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.84% | 6.17% | -0.33% |
Volatility
BIIB vs. BMY - Volatility Comparison
Biogen Inc. (BIIB) has a higher volatility of 9.88% compared to Bristol-Myers Squibb Company (BMY) at 6.06%. This indicates that BIIB's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIIB | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.88% | 6.06% | +3.82% |
Volatility (6M)Calculated over the trailing 6-month period | 24.17% | 18.48% | +5.69% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.22% | 26.64% | +6.58% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.45% | 23.98% | +14.47% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.48% | 25.24% | +16.24% |
Dividends
BIIB vs. BMY - Dividend Comparison
BIIB has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.57%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.57% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Financials
BIIB vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Biogen Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BIIB vs. BMY - Profitability Comparison
BIIB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported a gross profit of 0.00 and revenue of 2.48B. Therefore, the gross margin over that period was 0.0%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
BIIB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported an operating income of 0.00 and revenue of 2.48B, resulting in an operating margin of 0.0%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
BIIB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported a net income of 319.50M and revenue of 2.48B, resulting in a net margin of 12.9%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
Frequently Asked Questions
BIIB and BMY have a correlation of 0.44, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BIIB has higher volatility (9.88%) compared to BMY (6.06%). In terms of maximum drawdown, BIIB dropped -89.98% vs BMY's -72.03%.
BIIB currently has the higher Sharpe Ratio (1.47 vs 0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIIB and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer